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ITALIAN SUMMARY 
Premessa: La diagnosi e il profilo prognostico di un primo evento 
demielinizzante (ED) del sistema nervoso centrale non sono di immediata 
definizione. La diagnosi di sclerosi multipla e di altre possibili eziologie è basata 
su una combinazione di criteri che spesso richiedono un lungo monitoraggio per 
essere soddisfatti, dal momento che singoli test con elevata sensibilità e specificità 
al momento dell’evento iniziale sono limitati. I fattori predittivi di attività di 
malattia e disabilità dopo un primo ED sono conosciuti solo in parte. 
Scopo dello studio: Indagare il valore di tau, proteina 14-3-3 e cistatina C come 
marcatori biologici liquorali di un primo ED suggestivo di sclerosi multipla, oltre 
al significato prognostico dei dati ricavati dalla normale valutazione diagnostica 
iniziale. 
Metodi: Il liquido cerebro-spinale (LCS) di un gruppo di soggetti con un primo 
ED suggestivo di sclerosi multipla è stato testato per tau, proteina 14-3-3 e 
cistatina C. Inoltre, sono stati raccolti dati clinici, neurofisiologici, di risonanza 
magnetica e dell’analisi liquorale standard. Per confronto, sono stati analizzati 
anche campioni di LCS di pazienti con neuromielite ottica (NMO) o sindromi 
correlate, mielite trasversa acuta idiopatica (MTAi), malattia di Creutzfeldt-Jacob 
(CJ) e patologie prive di una componente neuro-infiammatoria o 
neurodegenerativa nota (non NIND). I marcatori liquorali sono stati testati sia in 
termini di significato diagnostico che prognostico. Nei casi di primo ED è stato 
analizzato anche il valore predittivo delle variabili cliniche, neurofisiologiche e di 
risonanza magnetica. Per l’analisi prognostica sono stati individuati i seguenti esiti 
clinici di interesse: recupero del primo ED, recidiva, conversione in sclerosi 
multipla, livello di disabilità neurologica (punteggio EDSS) raggiunto nel corso 
dell’osservazione clinica. 
Risultati: Sono stati inclusi nello studio 46 pazienti con un primo ED, 6 con 
NMO, 6 con MTAi, 8 con malattia di CJ e 11 con patologie non NIND. I 
soggetti con NMO o MTAi avevano livelli di tau significativamente più elevati sia 
rispetto ai casi con primo ED sia rispetto ai controlli con patologie non NIND, 
anche se inferiori rispetto ai pazienti con malattia di CJ. I casi con primo ED, 
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NMO e MTAi sono risultati positivi alla proteina 14-3-3 più frequentemente 
rispetto ai soggetti con patologie non NIND, sebbene una franca positività alla 
14-3-3 sia stata osservata molto più spesso nei pazienti con malattia di CJ. La 
concentrazione liquorale di cistatina C non differiva tra casi con primo ED, 
NMO, MTAi e patologie non NIND, ma era significativamente più elevata nei 
pazienti con malattia di CJ rispetto agli altri gruppi, con l’eccezione del gruppo 
NMO/MTAi. Dopo un’osservazione mediana di 6,7 anni (1,5-15,3), 39 casi con 
primo ED sono evoluti in sclerosi multipla, mentre 7 sono rimasti monofasici. 
Tau, 14-3-3 e cistatina C non sono risultate correlate con la gravità e il recupero 
del primo ED, con il rischio di conversione in sclerosi multipla né con la 
successiva disabilità e il tasso di ricadute nei pazienti con sclerosi multipla. 
L’esordio clinico grave era associato in modo indipendente al recupero 
incompleto del primo ED; la presenza di almeno tre lesioni periventricolari alla 
risonanza magnetica iniziale era predittiva di recidiva e conversione in sclerosi 
multipla; mentre il coinvolgimento piramidale all’esordio e il numero di recidive 
correlavano con la disabilità a lungo termine nei casi di sclerosi multipla. 
Conclusioni: La combinazione dei tre marcatori studiati ha fornito indicazioni sui 
processi patologici alla base di distinte malattie del sistema nervoso centrale. La 
tau liquorale ha dimostrato una potenziale utilità diagnostica nel differenziare i 
casi di primo ED suggestivo di sclerosi multipla dai casi di NMO/MTAi. 
Sebbene il pannello di marcatori proposto non abbia dimostrato un valore 
predittivo nei soggetti con un primo ED, i dati clinici, neurofisiologici e di 
risonanza magnetica si confermano in questo studio indicatori prognostici utili in 
questo gruppo di pazienti. 
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ABSTRACT 
Background: The diagnosis and the prognostic profile of an initial demyelinating 
event (IDE) of the central nervous system are not straightforward. The diagnosis 
of multiple sclerosis (MS) and other IDE etiologies stands on a combination of 
criteria often requiring a long follow-up to be fulfilled, since single tests with high 
sensitivity and specificity at the time of IDE presentation are limited. Predictors 
of disease activity and disability after an IDE are only partially known.  
Study aim: To investigate the value of tau, 14-3-3 protein and cystatin C as 
cerebrospinal fluid (CSF) biomarkers of IDEs suggestive of MS, in addition to 
the prognostic information provided by standard diagnostic evaluation. 
Methods: CSF samples of a group of subjects with IDEs suggestive of MS were 
tested for tau, 14-3-3 protein and cystatin C. Clinical, MRI, neurophysiological, 
and standard CSF analysis data were also collected. For comparison, CSF from 
patients with neuromyelitis optica (NMO) spectrum disorders, idiopathic acute 
transverse myelitis (iATM), Creutzfeldt-Jacob disease (CJD) and non-
inflammatory/non-neurodegenerative disorders (NINDDs) was also analyzed. 
CSF biomarkers were tested for diagnostic and prognostic significance. The 
predictive value of clinical, MRI, and neurophysiological variables was also 
analyzed in IDE cases. The outcomes of interest for prognostic analysis were: 
IDE recovery, relapse occurrence, conversion to MS, and subsequent disability 
level (EDSS score). 
Results: Forty-six patients with MS-like IDEs, 6 with NMO, 6 with iATM, 8 with 
CJD and 11 with NINDDs were included. NMO/iATM patients showed 
significantly higher tau levels compared to both NINDDs and IDEs, even if 
lower compared to CJD cases. IDE and NMO/iATM patients tested 14-3-3 
positive more frequently than NINDDs, although frank 14-3-3 presence was 
seen much more often in CJD cases. CSF cystatin C concentration did not differ 
between IDE, NMO/iATM, and NINDDs cases, but was significantly higher in 
CJD compared to other groups, with the exception of NMO/iATM cases. After 
a median follow-up of 6.7 (1.5-15.3) years, 39 IDE patients converted to MS, 
while 7 remained monophasic. CSF tau, 14-3-3 and cystatin C were not 
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correlated to IDE severity and recovery, to risk of MS conversion, or to 
subsequent disability and relapse rate in MS patients. Severe clinical onset was 
independently associated with incomplete IDE recovery, the presence of at least 
3 periventricular lesions on baseline MRI with relapse risk and conversion to MS, 
while initial pyramidal involvement and number of relapses with long-term 
disability in MS cases.  
Conclusions: The three combined biomarkers provided indications about the 
underlying pathological processes in distinct CNS disorders. CSF tau showed 
potential diagnostic utility in differentiating between IDEs suggestive of MS and 
NMO/iATM. Although the proposed CSF biomarkers panel seems to lack 
predictive value for IDEs, clinical, MRI and neurophysiological parameters are 
here confirmed as useful prognostic indicators in this group of patients.  
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RATIONALE AND AIMS 
An initial demyelinating event (IDE) of the central nervous system (CNS) 
may be defined as a first-ever episode of acute/subacute neurological disturbance 
suggestive of primary demyelination in one or more typical anatomical locations, 
such as optic nerve, spinal cord, brainstem, cerebellum, and cerebral hemisphere. 
An IDE may be monophasic (as it typically occurs in acute transverse myelitis 
[ATM] and acute disseminated encephalomyelitis) or may be the inaugural 
manifestation of a chronic demyelinating disorder of the CNS, such as multiple 
sclerosis (MS) and neuromyelitis optica (NMO). An IDE with features suggestive 
of MS is generally indicated as clinically isolated syndrome (CIS) and it represents 
the most frequent occurrence in the clinical practice. 
The differential diagnosis and the prognostic profile of a CIS are not 
straightforward, since the presenting clinical picture and initial diagnostic 
evaluation may overlap significantly across different disorders and between 
patients with good or poor recovery and with mild or severe disease, if MS 
develops. As a consequence, currently available diagnostic and prognostic tools 
are often insufficient to draw conclusions in the individual patient. In this view, 
molecular biomarkers – particularly if analyzed within the cerebrospinal fluid 
(CSF), which is contiguous to the pathological process – are promising source of 
information because of their potential to reflect specific biological pathways, to 
vary according to disease stage, and to be assessed quantitatively. Many molecular 
markers have been explored and most of them showed poor diagnostic 
specificity and/or poor prognostic sensitivity, with few exceptions (see below). 
Among the multitude of candidates, tau, 14-3-3 protein and cystatin C, which 
have an established diagnostic relevance in selected neurodegenerative disorders, 
have been studied in CIS and MS, with conflicting results. 
Tau is a microtubule-binding phosphoprotein, which plays an important role in 
axonal locomotion and intraneuronal transport. Tau proteins include six 
isoforms, with Mr ranging from 45 to 65 kDa, differing for the presence of either 
three or four repeats in the carboxy-terminal region of the molecule and the 
presence of one or two inserts in the amino-terminal domain. In normal 
  
6 
conditions, the CSF expresses low levels of tau protein (up to 250 pg/mL), while 
tau concentration is elevated in neurological disorders characterized by ongoing 
neuronal and axonal degeneration, such as CJD, stroke, and encephalitis. In AD 
and other tauopathies, hyperphosphorylated tau accumulates within the 
neurofibrillary tangles, and is released in the CSF, representing a valuable 
diagnostic and prognostic indicator of cognitive dysfunction (Mattsson et al., 
2009). Previous studies generally found higher CSF tau concentration in MS 
patients with both progressive and relapsing forms of the disease (including CIS), 
compared to controls (Kapaki et al., 2000; Martinez-Yelamos et al., Neurosci. Lett. 
2004; Bartosik-Psujek and Archelos, 2004; Brettschneider et al., 2005; Terzi et al., 2007; 
Frederiksen et al., 2011), although other researchers did not replicate this finding 
(Jiménez-Jiménez et al., 2002; Guimaraes et al., 2006; Teunissen et al., 2009). A 
correlation between CSF tau and poor short-term outcome of CIS/early MS has 
been found (Martinez-Yelamos et al., Neursoci. Lett. 2004; Brettschneider et al., 2006; 
Frederiksen et al., 2011), but no predictive value for disability has been shown at 
the time of initial event. 
14-3-3 protein belongs to a family of low Mr (30 kDa) polypeptides, existing in 
seven known human isoforms (β, γ, ε, η ζ, σ, and θ), which are expressed 
ubiquitously and are abundant in the human brain, where they represent about 
1% of total cytosolic proteins. 14-3-3 protein coordinates adaptation in protein-
protein interactions, acts as activator or suppressor, and regulates the subcellular 
localization of proteins, intervening in important cellular processes such as signal 
transduction, cell division, growth, adhesion, differentiation, apoptosis, stress 
response and malignant transformation (Obsillova et al., 2008). Owing to their 
abundant expression, damage to CNS tissue may potentially cause leakage of 14-
3-3 proteins into the CSF following cellular disruption. It is largely established 
that the ε and γ 14-3-3 isoforms are highly expressed in the CSF of patients with 
CJD, for which 14-3-3 protein detection represents a valuable diagnostic marker 
(Hsich et al., 1996; Chohan et al., 2010), but are also increased in the CSF of 
subjects with other neurological disorders characterized by active axonal 
degeneration, such as amyotrophic lateral sclerosis, encephalitis and stroke 
(Steinacker et al., 2011). Notably, in a number of neurodegenerative disorders, 
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increased CNS expression and/or tissue deposition of 14-3-3 proteins occur in 
the absence of concurrent CSF release. In Alzheimer’s disease (AD), the γ and ε 
isotypes are overexpressed in several brain regions, 14-3-3ζ is bound to 
neurofibrillary tangles, and 14-3-3η is a component of amyloid plaques (Layfield et 
al., 1996). However, 14-3-3s are essentially negative in the CSF of AD, with the 
exception of one study reporting a positive 14-3-3η essay in a small number of 
patients and one case report (Wiltfang et al., 1999; Jayaratnam et al., 2008). In 
neurodegenerative disorders with sequestration and aggregation of α-synuclein, 
such as Parkinson’s disease and dementia with Lewy bodies, 14-3-3 γ, ε, ζ, and θ 
isoforms are complexed with α-synuclein, but not expressed in the CSF 
(Kawamoto et al., 2002; Berg et al., 2003). CSF 14-3-3 protein has been also 
investigated in MS with a wide range of results. In 1999 Satoh et al. initially 
reported the presence of 14-3-3 protein in the CSF of a patient affected by 
relapsing-remitting MS in an active stage (Satoh et al., 1999). Subsequently, 14-3-3 
protein has been detected in the CSF of a certain proportion of subjects with 
CIS/MS by several (de Seze et al., 2002; Martinez-Yelamos et al., 2004; Bartosik-Psujek 
and Archelos, 2004; Colucci et al., 2004; Hein Née Maier et al., 2008) but not all 
research groups (Frederiksen et al., 2011). Presence of CSF 14-3-3 protein has been 
associated with a higher risk of MS conversion and subsequent disability in 
patients with CIS (Martinez-Yelamos et al., 2001). 
Cystatin C is a protease inhibitor expressed in the CNS by choroidal, 
leptomeningeal, glial and neuronal cells; it predominantly counteracts the action 
of cathepsins, a family of lysosomal proteins released by activated microglia and 
macrophages, and is thought to have a major role in modulating immune cell 
activation and inflammation-driven cell death (Reed, 2000). Cystatin C has been 
found to be downregulated in the CSF of a number of inflammatory conditions 
affecting the central nervous system and the peripheral nervous system (Yang et 
al., 2009). There is increasing evidence of a possible role of cystatin C in the 
pathogenesis of MS. Decreased levels of cystatin C, coupled with increased 
activity of cathepsin B, were found by Nagai and coworkers in the CSF of MS 
patients on relapse compared to controls (Nagai et al., 2000). In 2006 a study 
reported that the detection of a 12.5 kDa fragment of cystatin C was 100% 
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specific for CIS/MS (Irani et al., 2006), however other research groups later 
showed that the truncated peptide was the result of inadequate temperature 
storage of CSF samples (Hansson et al., 2007; Del Boccio et al., 2007). Sladkova and 
coworkers recently reported lower CSF cystatin C levels in patients with 
relapsing-remitting MS compared to CIS and control subjects (Sladkova et al., 
2011). In a previous study our group found increased cystatin C levels in patients 
with CIS, MS and idiopathic myelitis in remission compared to an internal 
control reference, using a semi-quantitative immunoblot method. In addition, we 
observed a significant correlation between CSF cystatin C level and long-term 
disability in a subgroup of patients with recurrent myelitis and spinal onset MS 
(Fiorini et al., 2007; Gajofatto et al., 2010). In an animal model of CNS 
demyelination, an increased expression of cystatin C and cathepsin B was found 
in white matter astrocytes and microglia, respectively, suggesting that during 
active stages of demyelination, microglia produce cathepsins while astrocytes 
release their inhibitor, cystatin C; dominance of cathepsins over cystatin C levels 
may contribute to myelin disruption, persistence of myelin debris, and 
impairment of remyelination (Ma et al., 2007).  
In an attempt to clarify the above mentioned issues, the present study aimed at 
investigating the diagnostic and prognostic significance of CSF tau, 14-3-3 
protein and cystatin C, as compared to clinical, radiological and 
neurophysiological variables in subjects with a CIS. 
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BACKGROUND 
DIFFERENTIAL DIAGNOSIS 
As diagnostic tests with sufficient sensitivity and specificity are limited, the 
definition of distinct IDEs etiologies may remain undetermined – e.g. idiopathic 
ATM – or require a long follow-up to fulfill current diagnostic criteria of chronic 
demyelinating disorders, such as MS and NMO. Other types of inflammatory and 
non-inflammatory disorders including infectious diseases, systemic autoimmune 
disorders, paraneoplastic syndromes, CNS tumors, and vascular disorders, may 
mimic an IDE (Miller et al., 2008). The clinical picture, medical history, imaging 
and laboratory tests usually distinguish such conditions one from the other and 
from inflammatory demyelinating disorders; in this latter group, however, distinct 
entities (e.g. MS, NMO, idiopathic ATM, etc.) may be difficult to separate, 
particularly at the time of initial symptoms. Additionally, systemic autoimmune 
diseases in which CNS manifestations are the initial symptoms can be extremely 
difficult to differentiate from demyelinating disorders. This is important because 
these various inflammatory conditions show relevant differences in terms of 
prognostic profile and treatment response. 
Multiple sclerosis 
MS is the cause of most IDE cases, being the most common chronic 
demyelinating disorder of the CNS. Pathogenesis is characterized by a complex 
interplay between genetic, autoimmune and environmental factors, but etiology is 
unknown. An IDE with presenting features suggestive of MS (CIS) is the type of 
onset in patients with the relapsing-remitting course of the disease (about 85% of 
initial cases), although not all CIS cases necessarily convert to MS. Subjects with 
primary progressive MS (about 15% of all cases) show insidious neurological 
deterioration which does not fit CIS definition. MS affects women twice as 
frequently as men and typically appears between 20 and 40 years of age, although 
an earlier or later onset may well occur. Typical CIS presentation includes acute 
partial myelitis (30-50% of cases), brainstem/cerebellum syndromes (25-30%) 
unilateral optic neuritis (20-25%), and cerebral hemisphere syndromes (5%); 
more than 20% of CISs present with symptoms and/or signs of more than one 
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anatomical location (multifocal presentation) (Confavreux et al., 2000; Tintoré et al., 
2005; Mowry et al., J Neurol Neurosurg Psychiatry 2009). CISs generally present with 
mild to moderate neurological symptoms, which often recover significantly in 
few weeks with or without treatment. An IDE with severe clinical features and 
poor recovery should prompt physicians to also consider diagnosis alternative to 
MS. Magnetic resonance imaging (MRI) of the brain and spinal cord showing at 
least one T2-hyperintense, well defined, ovoid, >5 mm diameter signal 
abnormality in at least 2 typical locations including periventricular, juxtacortical, 
infratentorial, or spinal cord regions, is strongly suggestive of MS (Montalban et al., 
2010). Negative or atypical MRI findings warrant further investigations to 
exclude other disorders (see below). Cerebrospinal fluid (CSF) findings typical of 
MS include normal biochemical parameters and protein concentration, normal or 
slightly increased cell count (≤10 cells/µl, predominantly lymphocytes), and 
evidence of oligoclonal bands or elevated IgG index (demonstrated in around 
70% of CIS case, but not specific for MS) (Sandberg-Wollheim et al., 1990). 
Neurophysiological studies support MS diagnosis in case of delayed conduction 
time with generally preserved amplitude and morphology of visual, 
somatosensory, motor, and/or brainstem evoked potentials (VEPs, SEPs, MEPs, 
and BAEPs, respectively), particularly if found within pathways that are not 
involved clinically, suggesting an ongoing multifocal demyelinating process of the 
CNS (Leocani and Comi, 2008). A diagnosis of MS requires the demonstration of 
CNS demyelinating lesions dissemination in space and time for which there is no 
better explanation; dissemination may be proved clinically and/or with the 
support of paraclinical evidence, particularly brain and spinal cord MRI. 
Standardized MRI parameters have been incorporated within worldwide accepted 
diagnostic criteria since 2001 (Poser et al., 1983; McDonald et al., 2001; Polman et al., 
2005). The most recently published criteria simplified MRI requirements in order 
to facilitate early diagnosis (dissemination in space and time may be demonstrated 
with a single scan in some cases) and uniform their application across different 
populations, apparently preserving sensitivity and specificity (Polman et al., 2011). 
Pathological studies of MS reveal several areas of demyelination, mostly located 
in the white matter of cerebral hemispheres and in corpus callosum but also 
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frequently in the brainstem, spinal cord and cerebral cortex. MS plaques are 
generally centered by a vein or venule and show variable degrees of inflammatory 
infiltrates, demyelination, axonal loss, and gliosis, depending on disease stage and 
clinical course. Active plaques are characterized by reduced density of myelinated 
fibers and irregular ensheathment of axons and are infiltrated by lymphocytes, 
macrophages and activated microglia, containing intracytoplasmic granules of 
myelin debris. Four distinct demyelination patterns have been proposed in MS, 
all characterized by prominent lymphocytes/macrophages infiltrates, plus 
immunoglobulin and complement deposition (pattern 2), oligodendrocytes 
apoptosis with preferential reduction of myelin-associated glycoprotein 
immunoreactivity (pattern 3), or oligodendrocytes loss with even reduction of 
various myelin proteins reactivity and no sign of apoptosis (pattern 4) (Lucchinetti 
et al., 2000). However, these findings have been independently replicated from 
other research groups only in part (Raine, 2008; Hu and Lucchinetti, 2009). 
Neuromyelitis optica 
NMO was initially described by Devic in 1894 as the simultaneous occurrence of 
severe transverse myelitis and bilateral optic neuritis with a fulminant 
monophasic clinical course, which is currently recognized as the type of onset of 
rare aggressive forms of the disorder. In fact, NMO typically is a relapsing-
remitting condition, in which optic neuritis and acute myelitis occur separately – 
several years apart from each other in some cases – and tend to be more severe 
and with poorer recovery, compared to MS. Bilateral involvement of the optic 
nerve has been described in several cases, and repeated attacks may lead to 
blindness (Merle et al., 2007). Acute transverse myelopathy is the typical clinical 
presentation of spinal cord involvement and it may cause a significant fixed 
disability even at the first episode; patients with good initial recovery often 
experience further spinal relapses with accrual of severe ambulatory disability 
(Collongues et al., 2010). A secondary progressive course is uncommon in NMO 
(Wingerchuk et al., 2007). While it had been thought for long that symptoms 
implicating other CNS regions excluded a diagnosis of NMO, in the last years a 
variety of neurological symptoms have been described that prove possible extra-
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opticospinal involvement, including neuroendocrine disturbances 
(hypothyroidism, galactorrhoea and diabetes insipidus due to hypotalamic 
involvement), intractable nausea and vomiting, refractory hiccup, and reversible 
posterior encephalopathy (Matà and Lolli, 2011). Although it is relatively rare in 
Europe and North America, NMO is the typical form of demyelinating disease in 
Asia and Africa. NMO pathogenesis is explained by an inflammatory 
autoimmune process predominantly against optic nerve and spinal cord tissue. At 
the pathological level, the lesions show extensive demyelination associated with 
cavitation, necrosis, and acute axonal injury of both white and gray matter, along 
with a pronounced loss of oligodendrocytes. The inflammatory infiltrates are 
composed of macrophages, eosinophils, neutrophils, and rare CD3+ and CD8+ 
T cells. In addition, there is a prominent perivascular deposition of 
immunoglobulin (mainly immunoglobulin M) and complement antigens, 
associated with vascular fibrosis, suggesting the relevance of humoral immunity 
mechanisms (Lucchinetti et al., 2002). In 2004, the identification of a specific 
immunologic serum marker was a significant step forward in the confirmation of 
this model. Lennon and coworkers reported that 73% of a group of patients with 
NMO were seropositive for an antibody named NMO-IgG; this antibody was 
found in less than 10% of patients with opticospinal MS and no patients with 
other neurologic or systemic autoimmune diseases (Lennon et al., 2004). Shortly 
after that discovery, NMO-IgG was characterized as an autoantibody selectively 
binding to the aquaporin 4 (AQP4) water channel, a component of the 
dystroglycan protein complex located in astrocytic foot processes at the blood-
brain barrier and highly expressed in the spinal cord and optic nerve (Lennon et al., 
2005). Roemer and others noted an early and selective absence of AQP4 
immunostaining in NMO lesions, compared with its persistence in acute MS 
plaques (Roemer et al., 2007). Thus, the binding of antibodies to AQP4 may be the 
initial pathogenic event in NMO. Currently, several NMO-IgG assays exist 
yielding similarly high specificity (around 100%) but different sensitivities (48-
77%). The fluorescence-activated cell sorting assay has the highest sensitivity 
(77%), followed by visual fluorescence-observation cell-based assay (73%), 
ELISA (60% with cut-off value of 5.0 U/ml and 70% with cut-off value of 1.6 
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U/ml), fluorescence immunoprecipitation assay (53%), and indirect immuno-
fluorescence assay (48%) (Waters et al., 2012). On MRI acute spinal cord lesions 
are characterized by central swelling typically extending over three or more 
vertebral segments. Brain MRI shows signal abnormalities in up to 60% of NMO 
cases; however, an MS-like pattern is seen very rarely. Brain lesions are generally 
ill-defined and predominantly located in periventricular areas of brainstem 
(fourth ventricle, periaqueductal region, and hypothalamus) and cerebral 
hemispheres, likely reflecting sites of preferential  AQP4 expression and 
explaining symptoms other than spinal cord or optic nerve dysfunction (Pittock, 
Weinshenker et al., 2006). The CSF of patients with NMO often reveals > 50 white 
blood cells/µl or > 5 neutrophils/µl, typically in the absence of oligoclonal bands 
and/or an increase in the IgG index. Current diagnostic criteria for NMO 
require: 1) optic neuritis, 2) acute myelitis, and 3) at least two of the following 
supportive criteria: a) a contiguous spinal cord MRI lesion extending over ≥ 3 
vertebral segments; b) onset brain MRI scan that is not diagnostic for MS; c) 
NMO-IgG seropositivity. These criteria appear to be an excellent diagnostic tool; 
however, differentiating between NMO and opticospinal MS is sometimes 
difficult. For example, some patients present with “incomplete” forms of NMO, 
such as isolated longitudinally extensive transverse myelitis (LETM), recurrent 
optic neuritis, or recurrent acute transverse myelitis with or without NMO-IgG 
positivity and no demonstration of MRI dissemination for a diagnosis of MS. 
Idiopathic acute transverse myelitis 
Patients presenting acute myelitis not attributable to MS, NMO, systemic 
autoimmune disease, or infection may have idiopathic ATM. This is largely an 
exclusion diagnosis, although structured diagnostic criteria have been proposed 
and applied in research and clinical settings (Transverse Myelitis Consortium Working 
Group, 2002; de Seze et al., 2005). They require: 1) acute bilateral sensory, motor, 
and/or sphincter spinal cord symptoms, 2) a well defined sensory level, and 3) 
prove of inflammation by CSF parameters (pleocytosis and/or IgG synthesis) 
and/or gadolinium-enhancing spinal cord lesion on MRI. Additionally, other 
conditions (e.g. spinal cord compression or infarct, infection, optic neuritis, MS, 
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connective tissue disease, arteriovenous malformations, etc.) need to be excluded. 
A considerable proportion of idiopathic ATM cases experience a preceding 
vaccination or infectious illness, although the specific etiological microorganism 
is identified only occasionally. There is no general consensus whether post-
infectious transverse myelitis is to be classified as idiopathic ATM or whether it is 
a distinct disorder. Epitope similarity between microorganisms and CNS proteins 
(molecular mimicry) is one of the most valid hypothesis to explain the 
pathogenetic mechanism of idiopathic ATM (Kerr and Ayetey, 2002). Idiopathic 
ATM is frequently severe and may determine significant residual disability. The 
clinical course is typically monophasic; however, cases of recurrent ATM of 
unknown cause with no clinical and radiological dissemination outside the spinal 
cord, absence of CSF oligoclonal bands and NMO-IgG seronegativity have been 
reported (Kim, 2003; Ravaglia et al., 2009). A subset of these patients have serum 
anti-Ro antibodies (Sjögren syndrome antibody – SSA) in the absence of systemic 
autoimmune disorder symptoms (Hummers et al., 2004). 
Acute disseminated encephalomyelitis (ADEM) 
ADEM is a severe inflammatory condition of the CNS, which may occasionally 
be difficult to distinguish from idiopathic ATM, NMO and MS, particularly in 
the pediatric population. It is characterized by acute or subacute onset of 
encephalopathy (consciousness alteration, behaviour changes and/or seizures), 
associated to various combinations of focal symptoms due to involvement of 
optic nerve, cerebral hemispheres, brainstem, cerebellum, and/or spinal cord. A 
preceding infectious illness is frequently reported and fever may anticipate or 
accompany the neurological manifestations. Typical laboratory findings in 
ADEM include elevations in the CSF protein and white blood cell count 
(lymphocytes), which are unusual in MS. Elevations of white blood cell count > 
50 cells/µl can be seen in both ADEM and NMO, in which however, more than 
5 neutrophils/µl are usually revealed. Oligoclonal bands are less frequently 
observed in ADEM compared to MS, but occasionally can be present. Brain MRI 
reveals large (>1 to 2 cm in size) confluent T2-hyperintense lesions that are 
multifocal, located in the supratentorial or infratentorial white matter regions, and 
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frequently gadolinium-enhancing; gray matter, especially basal ganglia and 
thalamus, is frequently involved. In rare cases, brain MRI shows a large single 
lesion, predominantly affecting white matter. Spinal cord MRI may show 
confluent intramedullary lesions or a single longitudinally extensive lesion with 
variable enhancement. ADEM pathology is characterized by ill defined areas of 
demyelination that surround venules and contain inflammatory infiltrates 
dominated by macrophages. Lesions are dispersed at multiple locations 
throughout the brain and spinal cord and appear of similar histological age (Hu 
and Lucchinetti, 2009). Although it is typically monophasic, ADEM may relapse 
either with the same symptoms and anatomical locations as in the initial event 
(recurrent ADEM) or with involvement of different areas (multiphasic ADEM) 
(Krupp et al., 2007). The response to steroid treatment is generally good and 
prognosis favorable, with complete clinical and radiological recovery in most 
cases. Patients with ADEM are at increased risk of developing MS later in life 
compared to the general population, suggesting a potential pathogenetic link 
between the two conditions (Menge et al., 2005). 
Systemic autoimmune disorders 
CNS involvement of systemic autoimmune disorders may represent a big 
challenge for IDEs differential diagnosis, since it can occur as the initial 
manifestation of the disorder itself (i.e. before appearance of systemic symptoms) 
and also because autoimmune conditions and inflammatory demyelinating 
diseases of the CNS may coexist in the same patient. Clinical, imaging and CSF 
features of neurological complications of rheumatic disorders may be 
undistinguishable from those of MS, NMO, or idiopathic ATM, although the 
pathogenetic mechanism is generally driven by vasculitis and/or small arteries 
thrombosis in the first group rather than demyelination as in the latter. Patients 
with systemic lupus erythematosus (SLE), antiphospholipid antibody syndrome, 
Sjögren syndrome, and immune-mediated vasculitides may experience transverse 
myelitis, optic neuritis, and other symptoms mimicking a demyelinating event, 
associated with presence of brain MRI abnormalities. Peripheral neuropathy, 
headache and psychiatric disturbances are frequently observed among or in 
  
16 
association with the neurological manifestations of the above mentioned 
disorders, while are uncommon in chronic demyelinating diseases such as MS and 
NMO (Theodoridou and Settas, 2006). The predominance of MRI lesions located at 
the cortical junction and static over time, as well as the concomitant finding of 
brain infarcts, calcification, or haemorrhages, suggesting small-vessel 
vasculitis/thrombosis, should always raise the suspicion of systemic 
immunomediated diseases. In these latter disorders, enhancing lesions and T1 
black holes are much less common than in MS. Asymptomatic spinal cord MRI 
lesions are rare in systemic autoimmune disorders, while lesions spanning over 3 
or more vertebral segments can be found in patients with ATM secondary to 
such conditions and can completely disappear after steroid or 
immunosuppressive treatment (Provenzale et al., 1994; Charil et al., 2006). CSF 
oligoclonal bands are relatively infrequent in systemic autoimmune diseases 
compared to MS, and they may be found in association with corresponding 
bands in the serum (a profile known as “mirror” pattern). Evoked potentials are 
normal in rheumatic disorders without clinical involvement of the underlying 
anatomical pathway, and when abnormal, evoked responses are more frequently 
reduced in amplitude rather than delayed in conduction as in MS (Ferreira et al., 
2005). 
Although subacute meningoencephalitis accounts for the vast majority of its CNS 
manifestations, Behçet’s disease may occasionally include symptoms and signs 
resembling those of IDEs, such as brainstem syndromes, acute myelitis, optic 
neuritis, and hemiparesis. Brain MRI abnormalities commonly consist of 
brainstem and basal ganglia lesions that can be extensive and associated with 
swelling and enhancement in the acute phase and that can shrink or disappear at 
follow-up. These lesions are usually associated with regional atrophy of the 
brainstem. Meningeal enhancement may be observed. In 20–40% of patients with 
Behçet’s disease and CNS involvement, cerebral white matter is diffusely 
involved. Cerebral venous sinus thrombosis is another manifestation of CNS 
involvement and can be detected on MRI and/or MRI angiography (Lee et al., 
2001). Spinal cord imaging may show various degrees of involvement, ranging 
from one isolated small lesion to a longitudinally extensive abnormality or 
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multiple cervico-dorsal lesions (Yesilot et al., 2007). CSF analysis often reveals 
modest protein and moderate white blood cell count increase (mostly neutrophils 
in the acute phase, replaced by lymphocytes in the chronic stage); oligoclonal 
bands are usually absent, although it has been reported that their presence may be 
transient (Al-Araji and Kidd, 2009; Serdaroglu, 1998). The neuropathology of 
Behçet’s disease in the acute phase is characterized by meningoencephalitis with 
an intense inflammatory infiltration including neutrophils, eosinophils, 
lymphocytes, and macrophages, with areas of necrosis and apoptotic neuronal 
loss. The brainstem, thalamus, basal ganglia, and white matter are all seen to be 
affected. In the progressive phase, the inflammatory infiltrates remain, although 
immunohistochemical staining for lymphocytes is less prominent (Hirohata, 
2008). 
Sarcoidosis is a multisystem granulomatous disease of unknown cause. The 
presence of CNS involvement is reported in 5–10% of patients. The specific 
manifestations depend on the anatomical location of the granulamatous lesions, 
although a diffuse cerebral and meningeal involvement is possible. Cranial nerve 
mononeuropathies (including optic neuritis), spinal cord, brainstem, and 
cerebellar syndromes are the most challenging differential diagnosis with IDEs. 
Brain and/or spinal cord MRI is abnormal in about 80% of patients with 
neurosarcoidosis and may reveal periventricular T2-hyperintense areas, multiple 
supratentorial and infratentorial brain lesions, a solitary intra-axial mass, optic 
nerve enhancement, and one or more spinal cord intramedullary lesions. Patients 
with neurosarcoidosis usually present with a simultaneous enhancement of 
multiple white-matter lesions; meningeal and punctiform parenchymal 
enhancement along Virchow-Robin spaces are additional features for differential 
diagnosis with MS. Another common feature of neurosarcoidosis is the presence 
of hydrocephalus (Christoforidis et al., 1999). Patients with spinal cord and/or optic 
nerve involvement associated with pituitary/hypothalamic dysfunction may be 
misdiagnosed as having NMO, especially in case of unremarkable brain MRI. 
CSF examination in neurosarcoidosis shows a nonspecific pattern of pleocytosis 
and elevated protein, particularly if meninges are involved; oligoclonal bands may 
be present and IgG index elevated. CSF levels of angiotensin-converting enzyme, 
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lysozyme, and beta2-microglobulin can be increased in over half of the patients. 
At the histological level, the diagnostic hallmark of sarcoidosis is the presence of 
granulomas in the involved tissue; granulomas are predominantly noncaseating, 
discrete, and surrounded by epithelioid cells and nodular inflammatory infiltrates 
consisting of multinucleated giant cells, macrophages, and lymphocytes (Hoitsma 
et al., 2004; Terushkin et al., 2010). 
PROGNOSTIC FACTORS 
Most of what is known about IDEs prognosis derives from several large studies 
on CIS patients, while predictive factors of non-MS like IDEs have been mostly 
explored in relatively small case series. This is greatly due to MS being much 
more common than other demyelinating disorders, but also to the extreme 
variability of its clinical picture and natural history and to the availability of 
several treatment options, compared to other conditions. When patients are 
diagnosed with an IDE, clinicians have to deal with many questions and 
challenges regarding not only differential diagnosis, but also the risk of 
subsequent relapses and disability and decision about disease-modifying therapy, 
which is likely to be effective in certain patients subgroups but could be 
superfluous in others (Roach, 2006). The following paragraphs will focus on 
prognostic factors of IDEs, particularly in relation to MS.  
Demographic and clinical predictors 
Studies of the natural history of IDEs use different groups of patients, either 
from observational studies or from placebo arms of therapeutic trials.  
Recovery of IDEs has been reported to be poorer in patients with older age, 
severe initial event, spinal cord presentation, and polyregional involvement (Beck 
et al., 1992; West et al., 2006; Mowry et al., J Neurol. 2009; Hirst et al., 2012). In the 
context of ATM, patients with shock-like symptoms and/or back pain at onset 
fail to recover in most cases (Lipton and Teasdall, 1973; Ropper and Poskanzer, 1978). 
ADEM usually recover in most cases; however, it has been reported that severity, 
recovery and mortality is worse in adult compared to pediatric cases (Ketelslegers et 
al., 2011). 
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After a CIS the rate of conversion to MS may vary greatly in relation to several 
factors. In a natural history study of a group of CIS patients in London (UK) the 
percentage who developed clinically definite MS (CDMS) was 43% at 5 years, 
59% at 10 years, and 68% at 14 years (Brex et al., 2002). The presenting symptoms 
did not seem to affect the rate of conversion to definite MS. A study of 308 
patients from the Gothenburg (Sweden) database found that 45 of 220 patients 
with a CIS still had a CIS at the 25 year follow-up (Eriksson et al., 2003). Patients 
with efferent lesions – mostly involving pyramidal and/or cerebellar systems – 
had twice the risk of a later diagnosis of MS than those without efferent lesions 
(optic neuritis and/or sensory symptoms). Another natural history study of 1215 
patients with MS in Lyon (France) found a longer period to the second episode 
with optic neuritis presentation than with either brainstem or spinal cord 
presentations (Confavreux et al., 2003). In another study, non-Caucasian ethnicity 
(HR 2.39) and younger age (HR 1.51 for each 10-year decrease in age) were 
reported to be strongly associated with an increased risk of having a second event 
within one year of CIS onset (Mowry et al., J Neurol. 2009). Data on medium-term 
outcome in untreated CIS are also available from five major clinical trials: the 
North American Optic Neuritis Treatment Trial (ONTT) (Beck et al., 1993); the 
Controlled High risk subjects Avonex Multiple sclerosis Prevention Study 
(CHAMPS) (Jacobs et al., 2000); the Early Treatment Of Multiple Sclerosis trial 
(ETOMS) (Comi et al., 2001); the Betaferon/Betaseron in Newly Emerging 
multiple sclerosis For Initial Treatment trial (BENEFIT) (Kappos et al., 2006), and 
the early glatiramer acetate treatment in delaying conversion to clinically definite 
multiple sclerosis in subjects Presenting with a Clinically Isolated Syndrome study 
(PRECISE) (Comi et al., 2009). The probability of a second episode during the 
study period was 17% in ONTT, 38% in CHAMPS, 45% in ETOMS, 45% in 
BENEFIT, and 43% in PRECISE. According to the results of some of these 
trials, the chance of developing clinically definite MS was greater in patients with 
a polyregional onset than in those with a unifocal onset.  
Female sex, older age at onset, and less severe motor impairment with the 
sentinel myelitis event have been reported as predictors of relapse in NMO 
(Wingerchuk and Weinshenker, 2003). The occurrence of a second attack after 
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ADEM in a pediatric population was associated with optic nerve involvement at 
onset, family history of CNS demyelination, and complete recovery of the first 
event (Mikaeloff et al., 2007). 
The likelihood of long-term irreversible disability is probably the most relevant 
concern for patients who develop or are at risk of developing a chronic 
demyelinating disease after an IDE. Irreversible disability may be the result of 
accumulation of fixed sequelae after one or more attacks or may be due to 
transition to a secondary progressive phase, in which insidious neurological 
deterioration substitutes a preceding relapsing-remitting stage of the disease. 
Secondary progression is common in MS (up to 75% of relapsing-remitting 
cases), rare in NMO and not observed in other demyelinating conditions such as 
ATM and ADEM (Runmaker and Andersen, 1993; Wingerchuck et al., 2007). 
Demographic and clinical predictors of disability in CIS patients who later 
develop MS include male gender, older age at onset, multifocal symptoms, 
efferent systems involvement, and incomplete remission of the initial event, 
although not all studies replicated the same findings (Weinshenker et al., 1991; 
Runmaker and Andersen, 1993; Confavreux et al., 2003; Tremlett et al., 2006; Debouverie 
et al., 2008; Koch et al., 2008). The relevance of age at MS onset as a prognostic 
factor, for example, is subject to interpretation depending on the temporal frame 
in which disability levels are captured. Indeed, while older age at onset is 
associated with a more rapid disability progression – likely due to prevalence of 
the primary progressive disease course, age-dependent degenerative processes, 
and dysfunction of repair mechanisms in older subjects – early onset MS patients 
reach disability milestones at a younger age compared to late onset MS cases, 
even though in a longer time interval (Confavreux and Vukusic, 2006; Tremlett et al., 
2006). This has been shown also in the pediatric population (Renoux et al., 2007). 
In this perspective, older age at onset may be viewed as favorable prognostic 
factor, meaning a longer disease-free interval before MS symptoms occurrence in 
life and an older age at which significant disability milestones are reached, 
compared to early onset (Tremlett et al., 2010). One single study reported a shorter 
time to secondary progressive MS in patients with family history of MS (Hensiek 
et al., 2007). 
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Even though the majority of CIS cases convert to MS at some point, a sizable 
proportion of MS patients does not accumulate irreversible disability during the 
entire natural history of the disease. This type of course is known as benign MS, 
although there is no general agreement on its definition and consequently, on its 
prevalence in the MS population (Hutchinson, 2012). While initial definitions 
predominantly stressed the absence of significant ambulatory disability (expanded 
disability status scale [EDSS] score < 3.5 or 2.5) after a reasonable time interval 
from initial symptoms (10 or 15 years) (Lublin and Reingold, 1996; Pittock et al., 
2004), more recent studies highlighted the importance of carefully considering 
cognitive status and quality of life when defining benign MS (Amato et al., 2008). 
Whatever the definition, it has been shown that benign status at 10 years after 
MS onset persist at 20 or more years in 52-69% of patients, leading to the 
conclusion that benign MS is a transient condition for a considerable proportion 
of cases (Pittock et al., 2004; Sayao et al., 2007; Ramsaransing and De Keyser, 2007). 
However, studies addressing this topic are generally limited by the clinic-based 
design which determines the possibility that MS patients with mild disease who 
are not seen on a regular basis in the neurology practices, are not included in the 
analysis falsely reducing the proportion of benign cases. There are no diagnostic 
tools or validated markers to identify CIS patients who will develop a mild form 
of MS; however, female gender, younger age, and absence of motor symptoms at 
onset have been indicated as predictors of a benign course (Costelloe et al., 2008). 
Long-term prognosis of subjects who develop NMO after an IDE is generally 
worse than in MS. NMO observational studies are mostly retrospective or cross-
sectional and include clinic-based treated populations. Clinical features associated 
with a poor outcome (severe disability or death) are blindness and/or sphincter 
involvement at onset, lack of recovery of the first attack, and high relapse rate in 
the first year of disease (Wingerchuk and Weinshenker, 2003; Cabre et al., 2009). A 
benign course of NMO – defined as EDSS score < 3.5 after at least 10 years 
from onset – has been described in a small subgroup of the population of an 
observational study (11 out of total 175 subjects, 41 with disease duration of 10 
years or longer); a good outcome was associated with Caucasian ethnicity and 
lower relapse rate. However, 3 of the 11 patients had a disabling attack later than 
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15 years from onset, questioning the existence of a truly benign form of NMO 
(Collongues et al., 2011). 
Imaging predictors 
As mentioned earlier, the presence, number, location, and size of signal 
abnormalities on brain and spinal cord MRI provide fundamental information for 
the differential diagnosis of IDEs etiologies. Additionally, baseline MRI features 
may predict the subsequent clinical evolution of IDEs, serving as a prognostic 
tool. 
In three observational prospective studies with a follow-up of 7, 15 and 20 years, 
CIS patients with mixed clinical syndromes (one study with optic neuritis only) 
and an abnormal brain MRI had a risk of relapse – an event that identifies such 
patients as having CDMS – of 65%, 72%, and 80%, respectively, while in CIS 
subjects with a normal scan the risk of conversion to CDMS was 8%, 25%, and 
20% (Tintoré et al., 2006; Optic Neuritis Study Group, 2008; Fisniku et al., 2008). 
Interestingly, there is a correlation between the number/location of MRI lesions 
at CIS onset and the risk of a subsequent relapse, allowing to classify patients as 
at low, medium, or high risk of developing MS. Over a follow-up period of 5 
years, CIS patients with 1-3, 4-9, and 10 or more lesions on initial brain MRI 
have a hazard ratio of converting to CDMS equal to 4.3, 7.4, and 19.3, 
respectively, compared to patients with no lesions. Moreover, initial MRI 
fulfilling 1-2, and 3-4 Barkhof’s criteria is associated with a hazard ratio of CDMS 
equal to 6.1 and 17.0, respectively, compared to MRI fulfilling none of the criteria 
(Tintoré et al., 2006). The Barkhof’s criteria, which were included in the 2001 and 
2005 versions of the McDonald’s diagnostic criteria for MS, are: 1) at least one 
gadolinium enhancing lesion or nine T2-hyperintense lesions; 2) one or more 
infratentorial lesion; 3) one or more juxtacortical lesion; 4) three or more T2 
periventricular lesions. Independent of other MRI features, patients who have at 
least one infratentorial lesion at onset have an increased risk of MS conversion, 
the risk being slightly higher in those with a lesion in the brainstem than in those 
with a lesion in the cerebellum (Tintoré et al., 2010). The number of spinal cord 
lesions at presentation of acute partial transverse mye
  
23 
with the number of relapses in patients who subsequently develop MS (Cordonnier 
et al., 2003). Among non-conventional MRI measures, the occurrence at 
presentation or early development of global or regional grey matter atrophy in 
patients with CIS has been associated with conversion to MS (Raz et al., 2010; 
Calabrese et al., 2011; Jenkins et al., 2011). 
The correlation between MRI lesions at CIS presentation and long-term disability 
in cases who develop MS is less robust than it is between MRI and risk of MS 
conversion. Some studies have shown that the number of baseline lesions is 
correlated with the confirmed EDSS score reached up to 20 years later (Optic 
Neuritis Study Group, 2008; Fisniku et al., 2008), while at least another study did not 
find such a correlation (Tintoré et al., 2006). In a study examining patients with 
initial optic neuritis, disability at 6 years was predicted by the presence at baseline 
of gadolinium enhancing lesions, spinal cord lesions, and number of infratentorial 
lesions (Swanton et al., Neurology 2009). In a different study including mixed CIS 
types, brainstem lesions on baseline MRI were associated with higher disability 
after 7 years (Tintoré et al., 2010). A high rate of lesion load increase in the short 
term after a CIS (particularly in the first 5 years) contributes to the development 
of subsequent disability (Li et al., 2006), but this is not predictable at CIS 
presentation and may be monitored only in the follow-up phase. Increase of MRI 
lesion load in the first few years after a CIS has also been associated with 
conversion to secondary progressive MS over a 20 years follow-up period 
(Fisniku et al., 2008). Overall, the correlation between MRI measures and 
disability in CIS/MS patient tends to be weak, likely due to conventional MRI 
detecting both clinically relevant and silent lesions, lacking specificity for 
distinguishing between the various biological substrates of lesions (edema, 
demyelination, gliosis, etc.), and lacking sensitivity for identifying potentially 
important tissue damage within normal appearing white and grey matter (Barkhof, 
2002; Goodin, 2006). 
Non-conventional MRI techniques – such as white/grey matter atrophy 
quantification, magnetic resonance spectroscopy, magnetization transfer, 
diffusion tensor, and functional imaging – have shown the ability to detect brain 
and spinal cord abnormalities in CIS and MS patients, which are not captured by 
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the classical lesion-based framework of conventional MRI. Findings reported in 
CIS patients include regional atrophy in cortical grey matter, deep grey matter 
and spinal cord (Calabrese et al., 2011; Henry et al., 2008; Audoin et al., 2010; Brex et 
al., J Neurol Neurosurg Psychiatry 2001), decreased N-acetyl aspartate in whole brain 
(Filippi et al., 2003) and normal-appearing white matter (Audoin et al., 2007; Wattjes  
et al., 2008), increased myoinositol in normal-appearing white matter (Fernando et 
al., 2004), decreased magnetization transfer ratio in white and grey matter 
(Fernando et al., 2005; Rocca et al., 2008), abnormal diffusion parameters in white 
matter (Henry et al., 2009; Raz et al., 2010), and abnormal functional MRI 
activation (Pantano et al., 2002; Filippi et al., 2004; Roosendaal et al., 2010). Low 
magnetization-transfer ratios in normal-appearing brain tissue of patients with 
CIS was reported to be an independent predictor of subsequent disease 
progression in one study (Iannucci et al., 2000), while other studies – with region-
of-interest or whole-brain-histogram analysis of magnetization-transfer MRI data 
– did not confirm such finding (Kaiser et al., 2000; Brex et al., Am J Neuroradiol 
2001). A functional MRI study found that CIS patients who had an MS-defining 
relapse over the subsequent year of follow-up showed at baseline a widespread 
recruitment of contralateral and ipsilateral cerebral areas not normally involved in 
a motor task compared to patients who did not develop clinically definite MS 
over the same period (Rocca et al., 2005). In patients with a CIS presenting as optic 
neuritis, it has been shown that voxel-based diffusion connectivity is abnormal in 
the optic radiation bilaterally (Ciccarelli et al., 2005) and magnetization transfer 
ratio is decreased bilaterally in the visual cortex (Brodmann’s area 17) when 
compared with healthy individuals (Audoin et al., 2006), suggesting post-synaptic 
changes and/or degeneration within visual pathways. Interestingly, one study 
found that magnetization-transfer ratio was lower in the optic nerves of patients 
with MS without recovery than in those with clinical recovery (Inglese et al., 2002). 
Additionally, Jenkins and coworkers reported that greater baseline functional 
MRI responses in higher visual areas (i.e. lateral occipital cortex) are associated 
with better visual outcome at 12 months in patients with acute optic neuritis, 
indicating neuroplasticity as an important mechanism for demyelinating events 
recovery (Jenkins et al., 2010). A recent study showed that decreased axial 
  
25 
diffusivity within the optic nerve predicted incomplete visual recovery in patients 
with a first event of optic neuritis (Naismith et al., 2012). The above mentioned 
findings show that non-conventional techniques have a high potential of 
providing quantitative measures that correlate with axonal/neuronal damage and 
neurological disability. However, most studies addressing this point have a cross-
sectional design and there is insufficient prospective data showing a robust 
correlation between such measures and long-term disability in patients with an 
IDE (Miller et al., 2012). 
Little is known about the prognostic significance of MRI in non-MS-like IDEs. 
Although a variety of brain and spinal cord MRI abnormalities are found in 
NMO spectrum disorders using both conventional and non-conventional 
techniques (Pittock, Lennon et al., 2006; Pichiecchio et al., 2011), none clearly predict 
the outcome of the initial event or the subsequent disease course. A retrospective 
study on 41 patients with NMO revealed no effect of the presence of brain MRI 
lesions both on relapse rate and progression of disability over more than 4 years 
of follow-up (Bichuetti et al., 2009). More recently, Collongues and coworkers 
reported that a high number of MRI brain lesions at NMO diagnosis was 
predictive of a residual visual acuity ≤1/10 after optic neuritis (Collongues et al., 
2010). In ADEM patients MRI does not seem to have a predictive value in the 
short-term recovery (Tenembaum et al., 2002); however, fulfillment of Barkhof’s 
and/or KidMUS (≥1 lesion perpendicular to long axis of corpus callosum; sole 
presence of well defined lesions) criteria on initial MRI in pediatric cases are 
associated with an increased risk of a second attack, suggestive of 
recurrent/multiphasic ADEM or MS (Dale et al., 2009). 
Neurophysiological predictors 
The relevance of neurophysiological assessment as a diagnostic tool in 
demyelinating disorders of the CNS progressively decreased in the last two 
decades, as MRI became largely available as a more sensitive technique. However, 
evoked potentials still maintain a prognostic significance, which have been 
especially demonstrated in MS. This is probably because evoked potentials are 
expression of the functional integrity of specific anatomical pathways and 
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consequently tend to better correlate with neurological disability than 
conventional MRI, which provide purely morphological information. Several 
cross-sectional and observational studies established that the degree of evoked 
potentials abnormalities is significantly associated with the EDSS score at the 
time of neurophysiological evaluation and up to 14 years later in patients with 
established MS (O’Connor et al., 1998; Fuhr et al., 2001; Leocani et al., 2006; Kallmann 
et al., 2006; Invernizzi et al., 2011; Schlaeger et al., 2012), while less is known about 
the predictive value of evoked potentials in patients with CIS. Evoked responses 
suggestive of demyelination at sites not clinically involved at CIS presentation 
raise the suspicion of MS, but the overall predictive value for relapse occurrence 
is low (Gronseth and Ashman, 2000). Hickman and coworkers reported that higher 
VEP amplitude predicted a better visual recovery after a first episode of acute 
unilateral optic neuritis (Hickman et al., 2004). A recent study found that CIS 
patients with at least three abnormal evoked potentials at baseline have an 
increased risk of reaching moderate disability over a mean follow-up period of six 
years, independent of initial MRI features (Pelayo et al., 2010). 
Absent cortical responses at motor and somatosensory evoked potentials and 
signs of denervation on electromyography have been associated with poor 
prognosis in patients with ATM (Kalita J et al., 1998). Watanabe et al. reported 
that the absence of VEPs P100 component was significantly related to the 
development of severe visual impairment (OR=35.4, p<0.001) in patients with 
NMO-like syndromes from a Japanese population (Watanabe et al., 2009). 
Molecular biomarkers 
Considering that clinical and paraclinical tools show a limited immediate 
capability of identifying the etiology and predicting the disease course in the 
individual patient with an IDE, biomarkers are promising source of information 
with a good potential of quantitative measure, sensitivity, and reliability. Ideally, 
reliable prognostic studies of biomarkers should fulfill some key methodological 
requirements, particularly: (1) prospective design; (2) sufficient follow-up 
duration; (3) adequate biomarker and outcome measurement; (4) clinical 
significance of the biomarker (i.e., good correlation and consistency with relevant 
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clinical outcomes); (5) reproducibility (Bielekova and Martin, 2004). Currently, very 
few biomarkers in the field of CNS demyelinating disorders have shown all of 
such characteristics. Although lumbar puncture is a relatively invasive procedure, 
CSF is the optimal biologic sample to analyze in CNS disorders. Considering the 
complex pathogenesis of demyelinating diseases, no single CSF molecule is 
expected to have absolute prognostic significance. However, families of 
biomarkers representative of specific pathogenetic pathways – particularly those 
related to axonal/neuronal damage – may correlate with irreversible neurological 
dysfunction and be used as prognostic indicators to identify patients at risk of a 
more aggressive disease course. Furthermore, such biomarkers may help in 
deciding treatment initiation and monitoring therapeutic efficacy. 
According to their biological role, molecules of potential prognostic significance 
for IDEs may be classified as follows: 
- markers of immune activation (e.g., cytokines, chemokines, antibodies, 
complement factors, adhesion molecules, etc.) 
- markers of blood-brain barrier disruption (e.g., matrix metalloproteinases) 
- markers of demyelination (e.g., myelin basic protein [MBP], myelin 
oligodendrocyte glycoprotein [MOG], proteolytic enzymes, proteases 
inhibitors etc.) 
- markers of axonal/neuronal and glial damage (e.g., neurofilaments, tau, 
14-3-3 protein, glial fibrillary acidic protein, etc.) 
- markers of remyelination/neural repair (e.g. nerve growth factor, brain-
derived growth factor, Nogo-A, etc.). 
A striking amount of papers have been published addressing the identification of 
molecular markers of CIS, MS, NMO and related disorders, but only a few have 
demonstrated a robust diagnostic value and even less have shown a clear 
predictive significance both in IDEs and during the course of established 
demyelinating disorders (Teunissen et al., 2005; Awad et al., 2010). Several CSF and 
blood markers have been associated with an increased risk of relapse after a CIS 
(i.e. conversion to clinically definite MS), including but not limited to: CSF 
oligoclonal IgG/IgM bands (Tumani et al., Neurobiol Dis. 2009; Garcia-Barragàn et 
al., 2009); CSF IgG index (Freedman et al., 2005); serum antibodies to MBP and 
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MOG (Berger et al., 2003); blood T cells differentiation transcription factors (Corvol 
et al., 2008; Frisullo et al., 2008); CSF immunoglobulins VH2 and VH4 sequences 
(Bennett et al., 2008); CSF 14-3-3 protein (Martinez-Yélamos et al., J. Neurol. 2004); 
CSF tau (Frederiksen et al., 2011); CSF neurofilament heavy chain (Brettschneider et 
al., 2006); CSF neurofilament light chain (Teunissen et al., 2009); CSF serin 
peptidase inhibitor; low CSF fetuin-A (Tumani et al., Neurosci Lett. 2009); CSF 
chemokine CXCL13 (Brettschneider et al., 2010); CSF chitinase 3-like 1 (Comabella et 
al., 2010); and low serum vitamin D (Mowry et al., 2010). However, for most of 
the candidates evidence is limited and/or results across studies are conflicting, 
and it remains unclear whether molecular markers may improve or even 
overcome the sensitivity and/or specificity of MRI in terms of prediction of MS 
development. CSF oligoclonal IgG bands represent an exception since their 
presence significantly and consistently increases the risk of relapse after a CIS, 
independent of MRI lesions dissemination (Tintoré et al., 2008), and in some cases 
proved to be superior to MRI in predicting such an outcome (Tumani et al., 
Neurobiol Dis. 2009). CSF IgG oligoclonal bands do not influence the long-term 
risk of disability after a CIS, although a contrasting observation has been 
described in patients with established MS (Joseph et al., 2009). CSF oligoclonal IgM 
reactive against myelin lipids have been associated with a poor CIS outcome in 
terms of time to conversion to MS, frequency of relapses and disability 
progression (Garcia-Barragàn et al., 2009). Vitamin D deficiency is implicated as a 
risk factor for MS; however, its role as an outcome predictor for patients with a 
CIS still awaits further confirmation (Ascherio et al., 2010; Mowry et al., 2010; Miller 
et al., 2012). 
Since axonal loss is regarded as the biological determinant of irreversible 
neurological disability in demyelinating disorders, CSF and blood markers of 
neuronal or CNS tissue injury are the most promising candidates for predicting 
disease progression. While several studies have explored the correlation between 
such markers and disability in established MS, few have addressed this topic in 
CIS (Teunissen et al., 2005). Neurofilament heavy and light chain proteins (NfH 
and NfL, respectively) concentrations are increased in the CSF of MS patients 
compared to age-matched normal controls, although they do not reach the levels 
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observed in neurodegenerative and more disruptive CNS disorders. Furthermore, 
CSF NfH and NfL levels seem to correlate with MS clinical course (higher levels 
in relapsing-remitting MS compared to CIS and in progressive compared to 
relapsing MS) and with disease activity (higher levels in CIS patients who convert 
to MS and during relapse compared to remission phase). Finally, it has been 
shown that CSF NfH and NfL concentrations may correlate with disease severity 
both at the time of lumbar puncture and at subsequent follow-up time points 
(Malmeström et al., 2003; Teunissen et al., 2009; Salzer et al., 2010; Kuhle et al., 2011). 
Tau and 14-3-3 protein have been already discussed in the previous section. A 
recent study showed an inverse correlation between CSF α-cleaved soluble 
amyloid precursor protein concentration and neurological disability in patients 
with CIS, MS, and NMO, although no significant differences emerged between 
the three diseased groups and healthy controls (Mai et al., 2011). 
In the context of IDEs suggestive of NMO, serum anti-aquaporin-4 antibody has 
mainly a diagnostic value, although it may also have a prognostic importance. 
NMO-IgG positivity predicts recurrence of attacks after a first event of isolated 
LETM (Weinshenker et al., 2006), is associated with poor recovery after optic 
neuritis (Matiello et al., 2008; Jarius et al., 2010), and correlates with long-term 
disability (Akman-Demir et al., 2011). Although there are no validated CSF 
prognostic markers for NMO at the time of initial event, increased CSF levels of 
glial fibrillary acidic protein and interleukin 6 may be predictive of a more severe 
disease course (Takano et al., 2010; Uzawa et al., 2011). 
The presence of 14-3-3 protein and increased levels of interleukin 6 in the CSF of 
patients with ATM have been proposed as potential predictors of permanent 
neurological disability (Irani and Kerr, 2000; Kaplin et al., 2005).  
Peculiar CSF chemokine and citokine profiles in patients with ADEM have been 
described; however, the prognostic significance of the biomarkers that have been 
identified is unknown (Franciotta et al., 2006; Ishizu et al., 2006). 
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METHODS 
STUDY CASES INCLUSION  
Patients with an IDE suggestive of MS (CIS) were retrospectively identified by 
means of medical charts review among patients seen at the Section of Clinical 
Neurology at Verona University Hospital. For this purpose, study subjects had to 
fulfill the following requirements: (1) Inclusion criteria: a) occurrence of a CIS, 
defined as the appearance of one or more neurological symptoms lasting at least 
24 hours, suggestive of MS-type acute or subacute demyelination in one or more 
of the following locations: optic nerve, cerebral hemisphere, brainstem, 
cerebellum, and spinal cord; b) follow-up duration 18 months or longer starting 
from symptoms onset; c) CSF sample collected within 6 months from symptoms 
onset or before a relapse occurred. (2) Exclusion criteria: a) history of previous 
episodes of CNS demyelination; b) CIS explained by a specific etiology other 
than MS, e.g. NMO (Wingerchuk et al., 2006), idiopathic ATM (Transverse Myelitis 
Consortium Working Group, 2002), or systemic autoimmune disorder, according to 
currently available diagnostic criteria; c) other concomitant CNS disorders. 
CLINICAL AND LABORATORY DATA 
CIS patients were seen at our site within one year from symptoms onset and then 
prospectively followed with follow-up visits not less than once a year. Initial 
evaluation included: medical history, physical and neurological examination, 
blood work-up including autoimmunity screening, brain and spine MRI, lumbar 
puncture (see CSF analysis section), and EPs. All follow-up visits included at least 
medical history and neurological examination. In patients who had a LETM or 
predominant optico-spinal involvement serum NMO Ig-G was assessed in our 
laboratory by tissue-based indirect immunofluorescence.  
The maximum degree of neurological impairment caused by the CIS was defined 
based on the expanded disability status scale (EDSS) functional systems scores 
as: (1) mild, one or more functional system with a score of 1, others 0; (2) 
moderate, one or two functional systems with a score of 2, others 0 or 1; (3) 
severe, at least one functional system with a score equal to or greater than 3 or at 
least three functional systems with a score of 2 (Kurtzke, 1983; Panitch et al., 2002).  
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Brain and spine MRI were performed at different sites with a 1 or 1.5 T machine 
within 6 months from CIS symptoms onset or before a relapse occurred. All 
patients had at least one follow-up MRI scan obtained at various time intervals to 
assess dissemination of lesions. Radiological data were obtained unblindly from 
original MRI scans of the brain and spinal cord. When scans were not available, 
data were collected from reports. Brain and spinal cord MRI were considered 
positive if there was at least one T2-hyperintense signal abnormality compatible 
with an MS lesion (Montalban et al., 2010). Lesion number, location and extension 
as well as gadolinium enhancement were assessed whenever possible. 
Dissemination in space was determined according to Polman’s criteria (Polman et 
al., 2005). 
EPs were performed at different sites within 6 months from CIS symptoms onset 
or before a relapse occurred. EPs were considered abnormal if the central 
conduction time was increased or significantly asymmetric, showed a significant 
morphologic alteration, or was not recognizable. The normative values were 
those used in the laboratory in which the electrophysiological evaluation was 
performed. 
For all CIS cases the following outcomes were considered: recovery from initial 
event, relapse occurrence, conversion to MS (Polman’s criteria), annual relapse 
rate, and disability level (EDSS score) at various follow-up time points (1.5, 3, 5 
years and last visit). A relapse was defined as an episode of new or recurring 
neurological symptoms suggestive of an inflammatory CNS lesion, lasting for at 
least 24 hours in the absence of increased body temperature or infection, after a 
remission of 30 days or more. Recovery from initial event was determined at 6 
months from symptoms onset or before a relapse or disability progression 
occurred and was scored as: (1) full, EDSS=0 and no residual symptoms; (2) with 
mild residual disability, EDSS=1.0-2.0 or EDSS=0 with residual symptoms; (3) 
with moderate to severe residual disability, EDSS=2.5 or more. 
CSF BIOMARKERS ANALYSIS 
Lumbar puncture was performed within 6 months from symptoms onset or 
before a relapse occurred, as requested by study inclusion criteria; timing was 
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classified as on acute phase if performed within 30 days from CIS symptoms 
onset. If not immediately analyzed, CSF samples were stored at −80 °C just after 
collection to ensure stability of biomarkers. All CSF analyses were performed 
blindly to clinical status of patients. Standard exam included protein 
concentration, cell count, IgG index, and oligoclonal bands assessment 
(isoelectrofocusing). Tau protein concentration was measured in duplicate using 
an ELISA kit (Innogenetics, Ghent, Belgium), according to the manufacturer's 
instructions. Tau concentrations were estimated from standard curves made for 
each assay. 14-3-3 protein was assayed by immunoblotting, after sodium dodecyl 
sulphate polyacrilamide gel electrophoresis (SDS-PAGE). For this purpose, 10 
µL of CSF was separated by SDS-PAGE and transferred to polyvinylidene 
difluoride (PVDF) membranes (Immobilon P; Millipore). Each gel included 10 
and 20 pg of recombinant 14-3-3 γ. Membranes were incubated with anti-14-3-3 
β polyclonal rabbit IgG cross-reacting with γ, ε, ζ, and η isoforms (Pan 14-3-3 
antibody SC-629; Santa Cruz Biotechnology), at 1:500 dilution, then incubated 
with anti-rabbit immunoglobulin at 1:3,000 dilution. The reaction was revealed by 
an enhanced chemiluminescence system (ECL; Amersham). The presence of the 
14-3-3 band was scored by two independent observers and classified as negative, 
weak positive, or positive based on comparison with recombinant 14-3-3 protein. 
Cystatin C concentration was measured in duplicate using a sandwich ELISA kit 
(Biovendor), according to the manufacturer’s instructions. Additionally, cystatin 
C was detected by immunoblotting, after SDS-PAGE. For this purpose, 10 µL of 
CSF was separated by SDS-PAGE and transferred to PVDF membranes 
(Immobilon P; Millipore). Each gel included recombinant cystatin C as positive 
control (lower detection limit 9.8 ng/ml). Membranes were incubated with an 
anti–cystatin C polyclonal antibody (Upstate Biotechnology) at 1:1000 dilution 
and revealed by an ECL system (GE Healthcare). Cystatin C concentration was 
estimated from standard curves made for each assay based on recombinant 
protein, using a dedicated software (UN-SCAN-IT GEL 6.1). 
For comparison with CIS cases, additional CSF samples were analyzed in patients 
with: 1) NMO spectrum disorders (n=6) or idiopathic ATM (n=6); 2) 
Creutzfeldt-Jacob disease (CJD, n=8); 3) non-inflammatory non-degenerative 
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disorders (NINDDs), including epidural anesthesia for surgical procedure (n=4), 
psychiatric disorders (n=3), lacunar syndrome (n=1), arteriovenous malformation 
(n=1), migraine (n=1), and cerebral palsy (n=1). Patients with NMO spectrum 
disorders included 4 NMO anti-AQP4 antibody positive, 1 NMO anti-AQP4 
antibody negative, and 1 recurrent LETM anti-AQP4 antibody positive subjects. 
Three of the 6 idiopathic ATM cases had a LETM and tested negative for anti-
AQP4 antibody. 
STATISTICAL ANALYSIS 
Differences between groups were analyzed by Kruskall-Wallis (with post-hoc 
Dunnett’s t statistic for multiple comparisons) and Mann-Whitney tests for 
quantitative variables (due to small and unequal sample size of groups) and by 
Chi-square or Fisher’s exact test for categorical variables, as appropriate. The 
correlation between quantitative variables and outcomes was analyzed computing 
either the Pearson’s or Spearman’s coefficient, as appropriate. To examine the 
predictive value of variables, multivariate logistic regression model analysis and – 
for time-to-event outcomes – Cox proportional hazards model analysis were also 
performed. A two-tailed significance level alfa=0.05 and 95% confidence 
intervals (CI) were adopted. All the analyses were performed using PASW 
Statistics 18 (SPSS Inc., Chicago, IL, USA). 
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RESULTS 
Forty-six subjects who experienced a CIS between 1996 and 2010 entered 
the study. Forty-three patients were prospectively followed at our site. Three 
patients were followed at other sites after the initial evaluation at our center; for 
these cases information were provided by the treating neurologist. In addition, 31 
control patients were included for CSF analysis as mentioned in the Methods 
section.  
CLINICAL AND LABORATORY DATA  
Descriptive characteristics of CIS cases are shown in Table 1. Variables 
associated with recovery from the initial event are shown in Table 2. At last 
available follow-up visit, 7 patients were still classified as CIS, while 39 had 
converted to MS according to Polman’s criteria. Ten patients (4 who had a 
LETM at presentation and 6 with predominantly optico-spinal manifestations) 
were assessed for NMO-IgG, which resulted negative in all cases. The presence 
of at least 3 periventricular (PV) lesions and at least 9 total lesions on baseline 
MRI were each associated with an increased risk of conversion to MS in the 
univariate Cox proportional hazards analysis (hazard ratio [HR]: 3.3, CI: 1.2-8.9, 
p=0.017 and HR: 2.1, CI: 1.01-4.4, p=0.047 respectively). Of the 46 CIS patients, 
37 had a clinical relapse, which in 34 cases was diagnostic of clinically definite 
MS. The presence of at least 3 PV lesions on initial brain MRI was the only 
predictor of the risk of conversion to clinically definite MS, using the Cox model 
(HR: 3.9, CI: 1.3-11.4, p=0.015). Median annual relapse rate was higher in MS 
patients with at least 9 lesions on initial MRI compared to patients with a lower 
lesion count (0.38 [0-1.2] vs 0.14 [0-0.9], p=0.006). The level of disability (EDSS 
score) reached by MS patients at the various follow-up time points was 
influenced by different baseline variables (Table 3). Additionally, final EDSS 
score was significantly correlated to the number of relapses occurring during 
follow-up (Spearman’s rho: 0.52, p=0.001). Moreover, the number of relapses 
predicted the risk of reaching a final EDSS score 2 or more, adjusting for initial 
pyramidal tract involvement and CIS recovery (HR: 1.2, CI: 1.1-1.4, p=0.04). 
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CEREBROSPINAL FLUID BIOMARKERS  
Results of biomarkers analysis are summarized in Table 4. Tau concentration was 
similar in CIS and NINDDs patients, while it was significantly higher in 
NMO/ATM compared to CIS cases (Figure 1), although not as high as in CJD 
patients (Table 4). Of the CIS and NMO/ATM patients, a small subgroup tested 
14-3-3 protein positive, while the majority had a weak positive assay, compared 
to NINDDs subjects who tested all negative and CJD cases who tested all 
positive (Figure 2). CIS patients had similar CSF cystatin C concentration 
compared to both NINDDs and NMO/ATM cases, but had a significantly lower 
concentration compared to CJD patients (Figure 3). Cystatin C immunoblotting 
detected the whole 13.4 kDa protein and no truncated fragments in all cases and 
controls (Figure 4). Interestingly, cystatin C and tau concentrations were 
significantly correlated, independent of diagnostic group, as shown in Figure 5.  
Within the CIS group, none of the biomarkers showed a statistically significant 
correlation with recovery, relapse occurrence, conversion to MS, relapse rate, and 
EDSS scores at the various time points. Among standard CSF analysis 
parameters, total protein concentration was associated with disability level in MS 
patients at 3 years (median EDSS score 3.5 [1.5-8.5] for patients with CSF protein 
>45 mg/dl vs EDSS score 1 [0-2.5] for patients with CSF proteins ≤45 mg/dl; 
p=0.04) and at 5 years (EDSS score 3.5 [1.5-8.5] for patients with CSF protein 
>45 mg/dl vs EDSS score 1.5 [0-4] for patients with CSF proteins ≤45 mg/dl; 
p=0.019) after onset. 
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DISCUSSION 
The present study explored tau, 14-3-3- protein and cystatin C in a group 
of patients with IDEs suggestive of MS both as potential diagnostic biomarkers – 
by comparison with other CNS disorders – and as possible predictors of clinically 
relevant outcomes, in addition to standard evaluation variables.  
Most CIS cases presented as acute myelitis, followed by brainstem/cerebellar 
syndromes. CIS severity was an independent predictor of incomplete recovery, 
which however, occurred with significant sequelae only in a minority of patients. 
Nearly 85% of CIS cases converted to MS during follow-up (74% converted to 
clinically definite MS). Presence of at least three PV lesions on initial brain MRI 
was the only independent predictor of both MS development defined according 
to Polman’s criteria and occurrence of a relapse. The high conversion rate to MS 
in this series compared to previous CIS studies may reflect selection bias of the 
retrospective identification of CIS cases in an MS-specialized center and the 
application of Polman’s criteria in our study. CIS patients had a significantly 
shorter follow-up duration compared to MS cases and were similar to MS 
patients in terms of clinical, neurophysiological, CSF and MRI characteristics, 
suggesting that CIS subjects would probably meet diagnostic criteria for MS with 
the prosecution of follow-up. In patients who developed MS, incomplete CIS 
recovery was an independent predictor of EDSS 1.5 or more at 18 months after 
onset, while pyramidal involvement at CIS and number of relapses during follow-
up where associated with the risk of EDSS score 2 or greater at the end of 
follow-up, in accordance with most previously published data. In some large 
observational studies, a short interval to the second event and high relapse rate in 
the first 2-5 years of MS were predictive of subsequent severe disability 
(Weinshenker et al., 1991; Confavreux et al., 2003; Tremlett et al., 2006; Debouverie et al., 
2008; Koch et al., 2008); however, one important study did not find this association 
(Runmaker and Andersen, 1993). According to the authors who found a positive 
correlation between relapses and long-term disability, the long term impact of 
relapses seems to be stronger in younger patients (<25 years old at MS onset), it 
diminishes significantly after the first 2-5 years of disease, and it is minimal after 
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the progressive phase has begun (Tremlett et al., 2009; Scalfari et al., 2010). Our 
findings confirm clinical parameters as useful prognostic indicators in patients 
with a CIS. 
The combined analysis of tau, 14-3-3 protein and cystatin C in the CSF of 
patients included in this study provided general indications about the underlying 
pathological processes in well distinct CNS disorders. For the three biomarkers 
there was an overall trend showing negative/normal values in NINDDs subjects, 
minimally altered values in CIS, moderately altered values in NMO/ATM, and 
markedly positive/elevated values in CJD, although statistical significance was 
not reached at each step. This trend may suggest a “neurodegenerative gradient” 
across disease groups, from no evidence of cell injury in “negative” controls 
through demonstration of massive neurodegeneration in CJD cases. Interestingly, 
we observed a significant correlation between CSF tau and cystatin C indicating 
the latter as a possible marker of axonal injury as well. 
CIS patients had normal CSF tau and cystatin C concentrations (i.e. similar to 
NINDDs controls who did not have any “active” neurological condition at the 
time of LP), while several CIS cases tested positive for 14-3-3 protein, suggesting 
that it may be detectable in the CSF in the absence of relevant neurodegenerative 
processes, as indicated by tau levels falling within the normal range. This finding 
is in accordance with several studies that reported normal CSF tau concentration 
in MS patients at various stages of the disease (including CIS), compared to 
controls (Jiménez-Jiménez et al., 2002; Guimaraes et al., 2006; Teunissen et al., 2009). 
On the other hand, other studies reported increased tau levels (Kapaki et al., 2000; 
Martinez-Yelamos et al., Neurosci. Lett. 2004; Bartosik-Psujek and Archelos, 2004; 
Brettschneider et al., 2005; Terzi et al., 2007; Frederiksen et al., 2011); however, they 
included patients who mostly were in the progressive phase of MS or on relapse, 
both characterized by a more obvious axonal damage and CSF tau release 
compared to patients in remission and/or after a single episode. CIS patients 
included in our study often underwent lumbar puncture well after the acute 
phase; additionally, they lacked a truly healthy control group to be compared 
with. Presence of 14-3-3 protein in the CSF of a certain proportion of CIS/MS 
patients has been consistently reported over the past decade (de Seze et al., 2002; 
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Martinez-Yelamos et al., 2004; Bartosik-Psujek and Archelos, 2004; Colucci et al., 2004; 
Hein Née Maier et al., 2008). The observation that presence of 14-3-3 protein is 
generally coupled with normal or slightly increased tau levels challenges the 
hypothesis that 14-3-3 is a marker of neuronal/axonal loss in MS, also 
considering that 14-3-3 protein isoforms expressed in CIS/MS patients 
(predominantly β and ζ) are substantially different from isoforms expressed in 
patients with neurodegenerative diseases (Fiorini et al., 2007). Moreover, no 
correlation between CSF 14-3-3 and positive OB or increased IgG index was 
found in CIS patients from the present study, in contrast with the hypothesis that 
humoral immunity driven inflammation in the CNS is related with 14-3-3 leakage 
in the CSF (Bartosik-Psujek and Archelos, 2004). In vitro studies have shown that 
14-3-3 protein interacts with vimentin and glial fibrillary acidic protein in cultured 
human reactive astrocytes derived from MS demyelinating lesions, and that 
astrocytes and oligodendrocytes, at the site of demyelinating lesions, show 
increased immunoreactivity for 14-3-3, suggesting that these cells might be the 
source of 14-3-3 in the CSF of MS patients (Kawamoto et al., 2004; Satoh et al., 
2004). Decreased CSF levels of cystatin C were previously reported in MS 
patients on relapse compared to controls (Nagai et al., 2000) and in patients with 
relapsing-remitting MS compared to CIS and control subjects (Sladkova et al., 
2011). Our group previously found increased cystatin C levels (measured by 
Western blot) in patients with CIS, MS and idiopathic myelitis in remission 
compared to an internal control reference (Fiorini et al., 2007; Gajofatto et al., 
2010). Since cystatin C is involved in such a dynamic process in CNS 
demyelinating disorders, it can be argued that its CSF concentration may 
fluctuate significantly depending on clinical course, disease stage, and treatment 
(Haves-Zburof et al., 2011), indicating the need of taking into account these factors 
when interpreting the diagnostic and prognostic significance of cystatin C and 
other biomarkers. 
In the current study, tau levels were significantly higher in patients with 
NMO/ATM cases compared to CIS, suggesting for the first time a potential 
diagnostic utility of this biomarker, to be confirmed in a larger sample including 
patients with established MS. This finding may be explained by the different 
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pathogenetic mechanisms underlying the two disease groups, characterized by 
more pronounced neuronal death and axonal loss in NMO/ATM than in MS. 
The distinction between CIS/MS and NMO may be extremely difficult in some 
cases; serum anti-aquaporin antibody exhibits high specificity but has relatively 
low sensitivity for the diagnosis of NMO. Alternative diagnostic biomarkers have 
been proposed, such as glial fibrillary acidic protein, which is significantly 
increased in the CSF of patients with NMO, with sensitivity and specificity 
approaching 100% when the reference group is limited to MS cases (Takano et al., 
2010; Petzold et al., 2011). Additionally, increased serum concentration of glial 
fibrillary acidic protein distinguished optic neuritis related to NMO from those 
related to MS or other conditions, in a study examining patients with various 
forms of idiopathic inflammatory optic neuropathy (Storoni et al., 2011). In a CSF 
proteomic analysis of NMO patients, Bai and coworkers showed that the most 
relevantly altered protein was haptoglobin, which was significantly up-regulated 
in NMO compared to control subjects with migraine and trigeminal neuralgia 
(Bai et al., 2010), while a previous study reported decreased CSF haptoglobin 
levels in CIS patients who converted to MS (Tumani et al., Neurosci. Lett. 2009). 
Interestingly, an Italian study reported that CSF and serum levels of N-acetyl 
aspartate were significantly higher in patients with MS compared to NMO and 
healthy controls; values of serum N-acetyl aspartate exceeding the 95th percentile 
of healthy controls were found in 100% of MS and none of NMO patients 
(Tortorella et al., 2011).  
None of the biomarkers analyzed in the present study was significantly associated 
with CIS severity and recovery, risk of MS conversion, subsequent disability, or 
relapse rate in MS patients. Brettschneider et al. found increased CSF tau levels in 
CIS patients who later converted to MS compared to non-converters, improving 
the sensitivity of MRI for the diagnosis of MS (Brettschneider et al., 2006); similarly 
Frederiksen et al. reported higher CSF tau concentration in patients with initial 
optic neuritis who developed MS compared to patients with monophasic optic 
neuritis (Frederiksen et al., 2011). Martínez-Yélamos et al. showed that a positive 
CSF 14-3-3 assay at the first neurological event suggestive of MS predicted 
conversion to clinically definite MS and development of significant neurological 
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disability over a median follow-up period of 33 months (Martínez-Yélamos et al., J. 
Neurol. 2004). There are discordant studies on the possible prognostic 
significance of CSF 14-3-3 in patients with established MS at the time of lumbar 
puncture (de Seze et al., 2002; Colucci et al., 2004). Our group previously reported a 
significant correlation between CSF cystatin C level – assessed by Western blot – 
and long-term EDSS score in a small subgroup of patients with recurrent myelitis 
and spinal onset MS (Gajofatto et al., 2010), a finding that was not replicated in the 
current study. However, Western blot may not be appropriate to quantify protein 
concentration and may show significant discrepancies compared to the ELISA 
method, which is more sensitive though less specific. 
The present study has some limitations, including the retrospective collection of 
clinical variables and outcomes, the relatively small sample size, and the absence 
of a completely normal control group for CSF analysis. On the other hand, we 
are comforted in our findings by the long follow-up of most CIS patients and the 
wide range of clinical, CSF, MRI and neurophysiological data, collected with 
relatively homogenous protocols. 
Research on biomarkers of IDEs may provide new insights into early 
pathological changes and pathogenetic mechanisms that might affect the course 
of the disease. Considering the complex pathogenesis of CNS demyelinating 
disorders, no single molecule is expected to have diagnostic and/or prognostic 
significance. However, families of biomarkers representative of specific 
pathogenetic pathways may support diagnosis and/or correlate with irreversible 
neurological dysfunction, identifying patients at risk of a more aggressive disease 
course (Bielekova and Martin, 2004). The identification of such biomarkers would 
be of paramount importance in guiding the approach and management of 
patients with an IDE. 
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TABLES AND FIGURES 
Table 1. Characteristics of CIS patients according to CIS or MS status at last follow-up 
Characteristic All cases 
n=46 
CIS→CIS 
n=7 
CIS→MS 
n=39 
p 
Gender (F/M) 30/16 5/2 25/14 .54 
Age at onset (years), mean ± SD 34.6 ± 8.9 36.2 ± 4.7 34.4 ± 9.4 .53 
Onset location, n (%) 
   spinal cord 
   brainstem/cerebellum 
   cerebral hemisphere  
   optic nerve 
   polyregional 
 
31/46 (67.4%) 
12/46 (26.1%)  
6/46 (13%) 
5/46 (10.9%) 
6/46 (13%) 
 
7/7 (100%) 
1/7 (14.3%)  
0 
0 
1/7 (14.3%) 
 
24/39 (61.5%) 
11/39 (28.2%)  
6/39 (15.4%) 
5/39 (12.8%) 
5/39 (12.8%) 
 
.08 
.66 
.57 
.99 
.99 
Impairment at onset, n (%) 
   mild/moderate 
   severe 
 
32/46 (69.6%) 
14/46 (30.4%) 
 
4/7 (57.1%) 
3/7 (42.9%) 
 
28/39 (71.8%) 
11/39 (28.2%) 
.66 
Recovery, n (%) 
   full 
   with mild disability 
   with moderate/severe disability 
 
17/46 (37%) 
28/46 (60.9%) 
1/46 (2.1%) 
 
1/7 (14.3%) 
6/7 (85.7%) 
0 
 
16/39 (41%) 
22/39 (56.4%) 
1/39 (2.6%) 
.34 
Brain MRI at onset, n (%) * 
   ≥1 MS-like lesion 
   0 MS-like lesions 
 
43/46 (93.5%) 
3/46 (6.5%) 
 
6/7 (85.7%) 
1/7 (14.3%) 
 
37/39 (94.9%) 
2/39 (5.1%) 
.39 
Spine MRI at onset, n (%) ** 
   ≥1 spinal cord lesion 
   0 spinal cord lesions 
 
35/39 (89.7%) 
4/39 (10.3%) 
 
7/7 (100%) 
0 
 
28/32 (87.5%) 
4/32(12.5%) 
.27 
Dissemination in space (MRI), n (%) 
   ≥9 lesions 
   ≥1 gad+ lesion  
   ≥3 PV lesions 
   ≥1 infratentorial lesion 
   ≥1 juxtacortical lesion 
   ≥3 Barkhof criteria 
   ≥2 MRI lesions + positive CSF 
 
20/40 (50%) 
21/32 (65.6%) 
29/41 (70.7%) 
39/45 (86.7%) 
27/39 (69.2%) 
29/41 (70.7%) 
30/46 (65.2%) 
 
1/6 (16.7%) 
5/6 (83.3%) 
2/6 (33.3%) 
6/6 (100%) 
5/6 (83.3%) 
5/7 (71.4%) 
4/7 (57.1%) 
 
19/34 (55.9%) 
16/26 (61.5%) 
27/35 (77.1%) 
33/39 (84.6%) 
22/33 (66.7%) 
24/34 (70.6%) 
26/39 (66.7%) 
 
.08 
.14 
.05 
.58 
.64 
.60 
.68 
EP at onset, n (%) 
   VEPs + 
   SEPs + 
   MEPs + 
   BAEPs + 
 
11/41 (26.8%) 
17/38 (44.7%) 
16/29 (55.2%) 
12/25 (48%) 
 
0/6 
1/6 (16.7%) 
3/5 (60%) 
1/3 (33.3%) 
 
11/35 (31.4%) 
16/32 (50%) 
13/24 (54.2%) 
11/22 (50%) 
 
.27 
.30 
.86 
.71 
Follow-up (years), median (range) 6.7 (1.5-15.3) 3.4 (2.0-7.2) 7.2 (1.5-15.3) .02 
Annual relapse rate, median (range) 0.2 (0-1.3) 0 0.3 (0-1.3)  
EDSS score, median (range) 
   at lumbar puncture (n=46) 
   at 1.5 years (n=46) 
   at 3 years (n=41) 
   at 5 years (n=29) 
   at last visit (n=46) 
 
2.0 (0-4.0) 
1.0 (0-8.5) 
1.5 (0-8.5)  
1.5 (0-8.5)  
2.0 (0-8.5) 
 
2.5 (0-3.5) 
1.0 (0-2.0) 
1.0 (1.0-2.0) n=5 
1.0 (1.0-1.0) n=3 
1.0 (0-2.0) 
 
2.0 (0-4.0) 
1.0 (0-8.5) 
1.5 (0-8.5) n=36 
1.5 (0-8.5) n=26 
2.0 (0-8.5) 
 
.38 
.68 
.52 
.17 
.05 
* 29/46: actual scan review; 17/46: data from radiological report 
** 24/39: actual scan review; 15/39: data from radiological report 
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Table 2. Predictors of CIS recovery 
  
 
Predictor 
Cases with  
complete 
recovery  
(EDSS=0) 
Cases with 
incomplete 
recovery 
(EDSS>0) 
Unadjusted OR 
(95%CI) 
for complete 
recovery* 
p 
Adjusted OR 
(95%CI) 
for complete 
recovery** 
p 
Pyramidal involvement 7 23     
No pyramidal involvement 10 6 5.5 (1.5-20.5) .01 2.7 (0.6-12.3) .21 
Moderate/severe impairment 10 27     
Mild impairment 7 2 9.5 (1.7-53.4) .01 1.9 (0.2-16.1) .55 
Initial EDSS score median (range) 1 (0-3.5) 2.5 (1-4) 0.3 (0.2-0.7) .002 0.4 (0.2-0.8) .009 
* Univariate logistic regression model 
** Multivariate logistic regression model adjusted for pyramidal involvement and initial EDSS score 
 
Table 3. Baseline predictors of disability level at various follow-up time points (MS cases) 
  
 
 
EDSS score at 1.5 years from CIS EDSS score at 5 years from CIS EDSS score at last visit EDSS ≥2 (time-to-event) 
Predictor 
median (range) 
OR (95%CI) for 
EDSS >1 
median (range) 
OR (95%CI) for 
EDSS ≥2 
median (range) 
OR (95%CI) for 
EDSS ≥2 
HR (95%CI) 
Male gender 1.5 (0-8.5) 2.4 (0.6-9.0) 1.75 (1-8.5) 1.3 (0.3-6.3) 1.75 (0-8.5) 0.7 (0.2-2.5) 0.8 (0.3-1.9) 
Female gender 1 (0-3.5)  1.5 (0-4.5)  2 (0-6.5)   
 p=.21* p=.21 p=.29* p=.78 p=.92* p=.55 p=.61 
Pyramidal system involvement 1.5 (0-8.5) 4.7 (1.1-20.9) 2 (0-8.5) 2.3 (0.4-12.1) 2 (0-8.5) 3.8 (0.9-15.2) 3.6 (1.3-10.1) 
No pyramidal system involvement 1.0 (0-2)  1.5 (0-2)  1.5 (0-3)   
 p=.04* p=.04 p=.24* p=.35 p=.04* p=.06 p=.02(3) 
Full CIS recovery 0 (0-2)  1 (0-3.5)  1.25 (0-3.5)   
Incomplete CIS recovery 1.5 (0-8.5) 13.1 (2.4-72.7) 2 (1-8.5) 5.0 (0.8-31.6) 2.0 (0-8.5) 2.4 (0.7-8.9) 3.1 (0.7-14.5) 
 p<.001* p=.003(1) p=.03* p=.09 p=.02* p=.19 p=.15 
Normal MEPs at onset 0 (0-2)  1 (0-2)  1.5 (0-3)   
Abnormal MEPs at onset 2 (1-3.5) 8.9 (1.4-56.6) 2.5 (1-4.5) 1.9 (0.3-11.6) 3 (1-6.5) 14.7 (1.9-109.2) 0.7 (0.2-3.0) 
 p=.002* p=.02 p=.04* p=.50 p=.002* p=.009(2) p=.63 
Normal SEPs at onset 0 (0-2)  1 (0-2)  1.5 (0-3)   
Abnormal SEPs at onset 1.5 (1-8.5) 1.5 (0.6-3.5) 1.75 (1-8.5) 0.7 (0.1-5.5) 2 (0-8.5) 0.7 (0.9-4.6) 0.6 (0.1-2.3) 
 p=.007* p=.39 p=.04* p=.67 p=.02* p=.68 p=.42 
DIS§ on initial MRI 1 (0-8.5) 3.4 (0.3-34.9) 2 (0-8.5) 2.3 (0.2-29.8) 2 (0-8.5) 3.0 (0.4-21.7) 2.5 (0.2-27.0) 
no DIS§ on initial MRI 0.75 (0-2)  1.25 (0-3.5)  0.75 (0-3.5)   
 p=.30* p=.31 p=.20* p=.54 p=.03* p=.28 p=.46 
* Mann-Whitney test 
(1) OR=9.2 (1.5-57.8) p=0.02 after adjusting for pyramidal system involvement and MEPs (other variables not significant in the model) 
(2) OR=12.2 (1.3-117.8) p=0.03 after adjusting for relapse rate and follow-up duration 
(3) OR=3.5 (1.2-10.2) p=0.02 after adjusting for relapse rate 
§ DIS: dissemination in space (fulfillment of 3 out of 4 Barkhof criteria) 
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Table 4. CSF biomarkers analysis 
Biomarker NINDDs CIS NMO/ATM CJD 
OB/IgG index 
n positive/increased (%) 
n negative/normal (%) 
n=8 
0 
8 (100%) 
n=46 
32 (69.6%) 
14 (30.4%) 
n=12 
6 (50%) 
6 (50%) 
N/A 
Tau  
ELISA (pg/ml) 
median (range) 
n=11 
 
130 (59-204) 
n=42 
 
204 (59-681)# 
n=12 
 
306 (86-971)# 
n=8 
 
>4000# 
14-3-3 
immunoblot 
n positive (%) 
n weak pos (%) 
n negative (%) 
n=11 
 
0 
0 
11 (100%) 
n=45 
 
4 (8.9%) 
24 (53.3%) 
17 (37.8%) 
n=11 
 
2 (18.2%) 
7 (63.6%) 
2 (18.2) 
n=8 
 
8 (100%)* 
0 
0 
Cystatin C 
ELISA (ng/ml) 
median (range) 
n=11 
 
2842 (595-9868) 
n=40 
 
3167 (1000-6922) 
n=10 
 
4231 (1861-8921) 
n=8 
 
5337 (3144-8534)§ 
# p<0.001 Kruskall-Wallis’ test; p=0.02 CIS vs NMO/ATM, p=0.001 NINDDs vs NMO/ATM, 
p<0.001 CJD vs each group (Dunnett’s t test) 
* p<0.001 CJD vs each group (χ2) 
§ p=0.01 p=0.01 Kruskall-Wallis’ test; p=0.004 CJD vs CIS, p=0.01 CJD vs NINDDs (Dunnett’s t test) 
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Figure 1. CSF tau concentration in the different diagnostic groups 
 
CJD patients are not shown because tau concentration was beyond the upper detection 
limits in all cases in this group 
 
 
Figure 2. CSF 14-3-3 protein assay in the different diagnostic groups 
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Figure 3. CSF cystatin C concentration in the different diagnostic groups 
 
 
 
Figure 4. Cystatin C detection by immunoblot in a sample of CIS cases 
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Figure 5. Correlation between CSF tau and cystatin C in CIS and control subjects 
 
Pearson’s r = 0.42 
p < 0.001 
n = 66 
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